Editorial Comment on Comparison of Infectious Complications After Transrectal Prostate Biopsy Under Two Antibiotic Prophylaxis Regimens: Ceftriaxone Plus Cefixime Versus Ciprofloxacin Plus Gentamicin
International Journal of Urology · 2026-05 · 33 (5)
DOI: 10.1111/iju.70464 ↗Kurz gefasst
Editorial in der Zeitschrift International Journal of Urology, online erschienen am 29.04.2026. Verfasst von Takanori Sekito und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
- Department of Bacteriology, Gunma University Graduate School of Medicine, Maebashi, Japan.
ORCID-Profile: Takanori Sekito, Takuya Sadahira
Zitieren
APA
Sekito, T., Hirakawa, H., & Sadahira, T. (2026). Editorial Comment on Comparison of Infectious Complications After Transrectal Prostate Biopsy Under Two Antibiotic Prophylaxis Regimens: Ceftriaxone Plus Cefixime Versus Ciprofloxacin Plus Gentamicin. International Journal of Urology, 33(5). https://doi.org/10.1111/iju.70464
Vancouver
Sekito T, Hirakawa H, Sadahira T. Editorial Comment on Comparison of Infectious Complications After Transrectal Prostate Biopsy Under Two Antibiotic Prophylaxis Regimens: Ceftriaxone Plus Cefixime Versus Ciprofloxacin Plus Gentamicin. International Journal of Urology. 2026;33(5). doi:10.1111/iju.70464
BibTeX
@article{Sekito2026,
author = {Sekito, Takanori and Hirakawa, Hidetada and Sadahira, Takuya},
title = {Editorial Comment on Comparison of Infectious Complications After Transrectal Prostate Biopsy Under Two Antibiotic Prophylaxis Regimens: Ceftriaxone Plus Cefixime Versus Ciprofloxacin Plus Gentamicin},
journal = {International Journal of Urology},
year = {2026},
volume = {33},
number = {5},
doi = {10.1111/iju.70464}
}
EUVIMED